NCT00997100 - Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

paquinimod (ABR-215757)

The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment

Trial Locations (4)

2100

Soren Jacobsen, Copenhagen

220 07

Dept of Rheumatology, University Hospital in Lund, Lund

171 76

Iva Gunnarsson M.D., Stockholm

751 85

Lars Rönnblom M.D., Uppsala